StockGlow

Tenax Therapeutics, Inc. (TENX)

Develops experimental heart failure and blood cancer medicines currently in clinical trials.

$15.80-0.02%Healthcare
Compare TENX with
StockGlow Score
92
Bullish
BearishBullish
1 year ago+154.0%

The outlook

Tenax Therapeutics (TENX) has strong analyst backing with a consensus "Strong Buy" and an average price target suggesting significant upside versus the current price. The stock is trading above both its 50- and 200-day moving averages, positioning it in the upper half of its 52-week range. Current sentiment leans notably bullish based on analyst views and technical positioning.

What’s behind the score

Analyst consensusStrong Buy — 1.1 avg of 10 analysts
Price trendAbove its 50- & 200-day averages
52-week range74% of the way from its 52-week low to high
Price targetAvg target +123% vs current price

Analyst price target

~12-month · 10 analysts
$35.20average target+122.8% vs now
Now $15.80
Low $26.00High $50.00

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$419.1M
52-wk high
$19.40
52-wk low
$5.78
50-day avg
$13.39
200-day avg
$12.15
Trailing P/E
—

Similar stocks

BPTHBio-Path Holdings, Inc.$0.04+5.26%VTVTvTv Therapeutics Inc.$31.08+0.19%PULMPulmatrix, Inc.$1.68-2.33%ADILAdial Pharmaceuticals, Inc.$2.95+4.98%CFORCapForce Inc.$9.51-47.17%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy